Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Rating Lowered by Lifesci Capital
Lifesci Capital lowered shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Free Report) from a strong-buy rating to a hold rating in a research report report published on Tuesday morning, Zacks.com reports. A number of other analysts also recently commented on CALT. HC Wainwright reiterated a neutral rating and set a $39.00 target price on […]
More Stories
Radius Recycling (NASDAQ:RDUS) Issues Quarterly Earnings Results
Radius Recycling (NASDAQ:RDUS – Get Free Report) released its earnings results on Tuesday. The basic materials company reported ($1.33) earnings...
RPM International (NYSE:RPM) Releases Earnings Results, Beats Expectations By $0.05 EPS
RPM International (NYSE:RPM – Get Free Report) announced its quarterly earnings results on Tuesday. The specialty chemicals company reported $1.39...
StockNews.com Initiates Coverage on Cumulus Media (NASDAQ:CMLS)
StockNews.com began coverage on shares of Cumulus Media (NASDAQ:CMLS – Free Report) in a research report report published on Wednesday....
Insider Selling: SentinelOne, Inc. (NYSE:S) CEO Sells 60,864 Shares of Stock
SentinelOne, Inc. (NYSE:S – Get Free Report) CEO Tomer Weingarten sold 60,864 shares of the stock in a transaction that...
BlackRock (NYSE:BLK) Coverage Initiated by Analysts at StockNews.com
StockNews.com assumed coverage on shares of BlackRock (NYSE:BLK – Free Report) in a research report report published on Wednesday morning....
Summit Materials (NYSE:SUM) Downgraded to Hold Rating by Stephens
Summit Materials (NYSE:SUM – Get Free Report) was downgraded by analysts at Stephens from a “strong-buy” rating to a “hold”...